Quantitative PCR and immunohistochemical analysis showed that LIF, LOX, MMP9, S100A4, SRPX2, and TIMP1 were expressed at high levels in glioma, whereas SLITI1 and SMOC1 were expressed at low levels, consistent with our previous results (Fig. 7; Fig. S4). Here, SRPX2 is linked to central nervous system cancer.